Evaluating the Role of Extended Aromatase Inhibitor Therapy in Early Hormone-Positive Breast Cancer

Evaluating the Role of Extended Aromatase Inhibitor Therapy in Early Hormone-Positive Breast Cancer Curr Breast Cancer Rep (2017) 9:183–187 DOI 10.1007/s12609-017-0250-y CLINICAL TRIALS (PF PEDDI, SECTION EDITOR) Evaluating the Role of Extended Aromatase Inhibitor Therapy in Early Hormone-Positive Breast Cancer 1 1 O. H. Vyas & V. G. Kaklamani Published online: 14 July 2017 Springer Science+Business Media, LLC 2017 . . Abstract Keywords Breast cancer Endocrine therapy Extended . . . Purpose of Review As adjuvant therapy for early-stage, endocrine therapy Aromatase inhibitors Adjuvant therapy hormone receptor-positive breast cancer has improved, late Hormone-positive breast cancer recurrences have become a significant issue. Endocrine therapies such as tamoxifen and aromatase inhibitors play a central role in reducing the risk of recurrence of hormone- Introduction positive breast cancers. However, the continued risk of breast cancer recurrence even with 5 years of adjuvant In 1896, Dr. George Beatson reported three cases of advanced AI therapy has led to interest in extended therapy. This breast cancer that improved after oophorectomy, the first re- review intends to discuss and analyze recent trials that port of successful endocrine therapy for breast cancer [1]. have reported results with extending AI therapy beyond Since then, the management of breast cancer has become in- 5 years of treatment. creasingly complex, with selective http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Current Breast Cancer Reports Springer Journals

Evaluating the Role of Extended Aromatase Inhibitor Therapy in Early Hormone-Positive Breast Cancer

Loading next page...
 
/lp/springer_journal/evaluating-the-role-of-extended-aromatase-inhibitor-therapy-in-early-g2BE2yqFes
Publisher
Springer US
Copyright
Copyright © 2017 by Springer Science+Business Media, LLC
Subject
Medicine & Public Health; Oncology; Internal Medicine; Surgical Oncology
ISSN
1943-4588
eISSN
1943-4596
D.O.I.
10.1007/s12609-017-0250-y
Publisher site
See Article on Publisher Site

There are no references for this article.

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

Monthly Plan

  • Read unlimited articles
  • Personalized recommendations
  • No expiration
  • Print 20 pages per month
  • 20% off on PDF purchases
  • Organize your research
  • Get updates on your journals and topic searches

$49/month

Start Free Trial

14-day Free Trial

Best Deal — 39% off

Annual Plan

  • All the features of the Professional Plan, but for 39% off!
  • Billed annually
  • No expiration
  • For the normal price of 10 articles elsewhere, you get one full year of unlimited access to articles.

$588

$360/year

billed annually
Start Free Trial

14-day Free Trial